Position:
Professor
Medical Director Adult Cystic Fibrosis Program, St Paul’s Hospital/UBC
Medical Director Providence Pulmonary Function Laboratiories
Division:
Respiratory
Research Interests:

Clinical research in areas of Cystic Fibrosis and Pulmonary manifestations of Connective Tissue Disorders

Personal:

Dr. Wilcox has had a focus on academic educational activities at national, international and local levels. He is a member of the Scientific Organizing Committee for the Annual Canadian Thoracic Society meeting and a member of the Organizing Committee for the UBC Division of Respirology Annual CME Update meeting. He is a member of the organizing committee of the Annual Western Canadian Cystic Fibrosis meeting.

Dr. Wilcox is a member of the Data and Safety Monitoring Board for the US Cystic Fibrosis Foundation, which reviews all appropriate studies funded by this organization. He is a member of the UBC Dept. Medicine Peer Review Committee.

Dr. Wilcox is the Lead of the Cystic Fibrosis Provincial Initiative funded by the Specialists Services Commission (SSC) after a multispecialty completion. The award is for 3 years and incorporates Pediatric and Adult CF initiatives.

Dr. Wilcox’s research has been focused on his clinical subspecialty interests of Cystic Fibrosis, Connective Tissue Pulmonary Diseases. As the Medical Director of one of the largest Adult CF Clinics in Canada there have been opportunities to partner with other researchers in Canada to address important clinical issues. He collaborates with Dr. Brad Quon and other UBC investigators and Canadian colleagues in clinical work in Cystic Fibrosis. The UBC Adult CF clinic has been selected as one of the inaugural sites for the Canadian CF Clinical Trials Network (CFCanACT) and Dr. Wilcox will be a co site lead. He will assume the role of DSMB coordinator for this network. He was a co supervisor of Dr. Kate Skolnik who has just completed a Clinical and Research Fellowship in Cystic Fibrosis at UBC.

In the area of Connective Tissue Disorders Dr. Wilcox is a co director of the Scleroderma Respiratory clinic. In conjunction with Dr. Chris Ryerson and Jim Dunne he has participated in studies that evaluate predictors of disease progression, the role of rehabilitation and the utility of novel biomarkers. Dr. Wilcox coordinates the Scleroderma Biobank at UBC collecting data and samples from over 150 Scleroderma patients.

Dr. Wilcox is a coinvestigator of a research consortium in North America evaluating patients with Hereditary Hemorrhagic Telangiectasia (Dr. Marie Faughnan PI) involved in a NIH sponsored study examining brain vascular malformations.

Dr. Wilcox is the Past President of the Canadian Thoracic Society after being elected by his peers to the CTS Executive 6 years earlier. His term runs until April 2019.

Education:
Queen’s University, MD
University of Western Ontario, Intern
MD University of Western Ontario, Resident
University of British Columbia, Fellowship
Recent Publications:

Referred Publications

(a) Journals

1.Wilcox PG, Ahmad D, Darke AC, Parsons J, Carruthers SG. Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther. 1986 Jan;39(1):29-34.
2.Wilcox P, Miller R, Miller G, Heath J, Nelems B, Muller N, et al. Airway involvement in ulcerative colitis. Chest. 1987 Jul;92(1):18-22.
3.McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med. 1988 Oct;148(10):2231-6.
4.Wilcox P, Baile EM, Hards J, Muller NL, Dunn L, Pardy RL, et al. Phrenic nerve function and its relationship to atelectasis after coronary artery bypass surgery. Chest. 1988 Apr;93(4):693-8.
5.Wilcox PG, Eisen A, Wiggs BJ, Pardy RL. Diaphragmatic relaxation rate after voluntary contractions and uni- and bilateral phrenic stimulation. J Appl Physiol. 1988 Aug;65(2):675-82.
6.Wilcox PG, Morrison NJ, Anzarut AR, Pardy RL. Lambert-Eaton myasthenic syndrome involving the diaphragm. Chest. 1988 Mar;93(3):604-6.
7.Wilcox PG, Pare PD, Fleetham JA. Conditioning of the diaphragm by phrenic nerve pacing in primary alveolar hypoventilation. Thorax. 1988 Dec;43(12):1017-8.
8.Wilcox PG, Stein HB, Clarke SD, Pare PD, Pardy RL. Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus. Chest. 1988 Feb;93(2):352-8.
9.Blackie SP, Fairbarn MS, McElvaney GN, Morrison NJ, Wilcox PG, Pardy RL. Prediction of maximal oxygen uptake and power during cycle ergometry in subjects older than 55 years of age. Am Rev Respir Dis. 1989 Jun;139(6):1424-9.
10.McElvaney G, Blackie S, Morrison NJ, Wilcox PG, Fairbarn MS, Pardy RL. Maximal static respiratory pressures in the normal elderly. Am Rev Respir Dis. 1989 Jan;139(1):277-81.
11.McElvaney G, Fairbarn MS, Wilcox PG, Pardy RL. Comparison of two-minute incremental threshold loading and maximal loading as measures of respiratory muscle endurance. Chest. 1989 Sep;96(3):557-63.
12.McElvaney GN, Blackie SP, Morrison NJ, Fairbarn MS, Wilcox PG, Pardy RL. Cardiac output at rest and in exercise in elderly subjects. Med Sci Sports Exerc. 1989 Jun;21(3):293-8.
13.Wilcox P, Andolfatto G, Fairbarn MS, Pardy RL. Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. Am Rev Respir Dis. 1989 Jan;139(1):157-63.
14.Wilcox PG, Hards JM, Bockhold K, Bressler B, Pardy RL. Pathologic changes and contractile properties of the diaphragm in corticosteroid myopathy in hamsters: comparison to peripheral muscle. Am J Respir Cell Mol Biol. 1989 Sep;1(3):191-9.
15.Wilcox PG, Pardy RL. Diaphragmatic weakness and paralysis. Lung. 1989;167(6):323-41.
16.McElvaney GN, Wilcox PG, Fairbarn MS, Hilliam C, Wilkins GE, Pare PD, et al. Respiratory muscle weakness and dyspnea in thyrotoxic patients. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1221-7.
17.Wilcox PG, Morrison NJ, Pardy RL. Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest. 1990 Sep;98(3):620-6.
18.Wilcox PG, Pare PD, Pardy RL. Recovery after unilateral phrenic injury associated with coronary artery revascularization. Chest. 1990 Sep;98(3):661-6.
19.Wilcox PG, Pare PD, Road JD, Fleetham JA. Respiratory muscle function during obstructive sleep apnea. Am Rev Respir Dis. 1990 Sep;142(3):533-9.
20.Blackie SP, Fairbarn MS, McElvaney NG, Wilcox PG, Morrison NJ, Pardy RL. Normal values and ranges for ventilation and breathing pattern at maximal exercise. Chest. 1991 Jul;100(1):136-42.
21.Cala SJ, Wilcox P, Edyvean J, Rynn M, Engel LA. Oxygen cost of inspiratory loading: resistive vs. elastic. J Appl Physiol. 1991 May;70(5):1983-90.
22.Wilcox P, Osborne S, Bressler B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility. Am Rev Respir Dis. 1992 Aug;146(2):462-6.
23.Awadh N, Ronco JJ, Bernstein V, Gilks B, Wilcox P. Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. Chest. 1994 Nov;106(5):1622-4.
24.Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ. Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol. 1994 Mar;76(3):1060-7.
25.Wilcox PG, Bassett A, Jones B, Fleetham JA. Respiratory dysrhythmias in patients with tardive dyskinesia. Chest. 1994 Jan;105(1):203-7.
26.Wilcox PG, Wakai Y, Walley KR, Cooper DJ, Road J. Tumor necrosis factor alpha decreases in vivo diaphragm contractility in dogs. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1368-73.
27.Keenan SP, Alexander D, Road JD, Ryan CF, Oger J, Wilcox PG. Ventilatory muscle strength and endurance in myasthenia gravis. Eur Respir J. 1995 Jul;8(7):1130-5.
28.Jiang TX, Cairns A, Road JD, Wilcox PG. Effect of the beta-agonist clenbuterol on dexamethasone-induced diaphragm dysfunction in rabbits. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1778-83.
29.Wilcox P, Milliken C, Bressler B. High-dose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor. Am J Respir Crit Care Med. 1996 May;153(5):1611-5.
30.Clark HE, Wilcox PG. Noninvasive positive pressure ventilation in acute respiratory failure of chronic obstructive pulmonary disease. Lung. 1997;175(3):143-54.
31.Frangolias DD, Nakielna EM, Wilcox PG. Pregnancy and cystic fibrosis: a case-controlled study. Chest. 1997 Apr;111(4):963-9.
32.Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittmann R, et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1572-7.
33.Stewart IB, Sheel W, Frangolias DD, Wilcox PG, McKenzie DC. The effect of nitric oxide inhalation on pulmonary gas exchange and exercise capacity in patients with Cystic Fibrosis. Clin Exer Physiol. 2001;3(1):44-48.
34.Frangolias DD, Wilcox PG. Predictability of oxygen desaturation during sleep in patients with cystic fibrosis : clinical, spirometric, and exercise parameters. Chest. 2001 Feb;119(2):434-41.
35.Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001 Nov 1;33(9):1469-75.
36.Frangolias DD, Holloway CL, Vedal S, Wilcox PG. Role of exercise and lung function in predicting work status in cystic fibrosis. Am J Respir Crit Care Med. 2003 Jan 15;167(2):150-7.
37.Frangolias DD, Pare PD, Kendler DL, Davidson AG, Wong L, Raboud J, et al. Role of exercise and nutrition status on bone mineral density in cystic fibrosis. J Cyst Fibros. 2003 Dec;2(4):163-70.
38.Frangolias DD, Ruan J, Wilcox PJ, Davidson AG, Wong LT, Berthiaume Y, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):390-6.
39.Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005 Aug 6-12;366(9484):463-71.
40.Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. 2005 Nov 15;41(10):1483-97.
41.Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, Bertiamme Y, Brown N, Wilcox PG, et.al. Combination antibiotic susceptibility testing to treat exacerbations of Cystic Fibrosis associated with multiresistent bacteria: a Randomized double blind controlled clinical trial. Lancet 2005;355:463-71.
42.Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006 Nov;61(11):969-74.
43.Al Lawati NM, Wilcox P. Paradoxical embolization in an adult cystic fibrosis patient. Can Respir J. 2007 Jul-Aug;14(5):293-4.
44.Blohmke CJ, Victor RE, Hirschfeld AF, Elias IM, Hancock DG, Lane CR, et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol. 2008 Jun 1;180(11):7764-73.
45.Miller RJ, Tildesley HD, Wilcox PG, Zhang H, Kreisman SH. Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study. Can Respir J. 2008 Sep;15(6):291-4.
46.Ryerson CJ, Churg A, Wilcox PG. A 48-year-old woman with remote hodgkin disease and bilateral pleural effusions. Chest. 2009 Sep;136(3):934-7.
47.Vandemheen KL, O’Connor A, Bell SC, Freitag A, Bye P, Jeanneret A, et al. Randomized trial of a decision aid for patients with cystic fibrosis considering lung transplantation. Am J Respir Crit Care Med. 2009 Oct 15;180(8):761-8.
48.Pandey AK, Wilcox P, Mayo JR, Sin D, Moss R, Ellis J, et al. Predictors of pulmonary hypertension on high-resolution computed tomography of the chest in systemic sclerosis: a retrospective analysis. Can Assoc Radiol J. 2010 Dec;61(5):291-6.
49.Tseng OL, Kelsall JT, Wilcox PG. Piperacillin-associated pulmonary infiltrates with eosinophilia: a case report. Can Respir J. 2010 Mar-Apr;17(2):e24-6.
50.Dunne JV, Chou JP, Viswanathan M, Wilcox P, Huang SH. Cardiac tamponade and large pericardial effusions in systemic sclerosis: a report of four cases and a review of the literature. Clin Rheumatol. 2011 Mar;30(3):433-8.
51.Quon BS, Reid JD, Wong P, Wilcox PG, Javer A, Wilson JM, et al. Burkholderia gladioli – a predictor of poor outcome in cystic fibrosis patients who receive lung transplants? A case of locally invasive rhinosinusitis and persistent bacteremia in a 36-year-old lung transplant recipient with cystic fibrosis. Can Respir J. 2011 Jul;18(4):e64-5.
52.Zlosnik JE, Costa PS, Brant R, Mori PY, Hird TJ, Fraenkel MC, et al. Mucoid and Nonmucoid Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Infections. Am J Respir Crit Care Med. 2011 Jan 1;183(1):67-72.
53.Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, Paterson N, Wilcox P, Rabin H, Tullis E, Morrison N, Ratjen F Treatment of Aspergillus Fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo Controlled Pilot Study PLos ONE 74 e 36077 2012
54.Yang D , Wilson JM , Bai C , Yee J , Wilcox PG , Khalil N , Levy RD, “Acute exacerbation of pulmonary fibrosis following single lung transplantation.”, Can Respir J, 19(1)e:3-4, 2012
55.Weller ME , Safronova AS , Clementson J , Kantsyrev VL , Safronova UI , Beiersdorfer P , Petkov EE , Wilcox PG , Osborne GC, “Extreme ultraviolet spectroscopy and modeling of Cu on the SSPX Spheromak and laser plasma “Sparky”.”, The Review of scientific instruments, 83(10) 2012
56.Iosfina I , Chuo JY , Godinho DV , Wilcox PG , Kreisman SH , Quon BS, “Optic disc swelling and vision loss in a patient with cystic fibrosis and diabetes.”, Case Rep Endocrinol 2013:843795, 2013.
57.Shoki AH , Mayer-Hamblett N , Wilcox PG , Sin DD , Quon BS, “Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.”, Chest 144(5):1659-70, 2013.
58.Hui P , Mattman A , Wilcox PG , Wright JL , Sin DD, “Immunoglobulin G4-related lung disease: A disease with many different faces.”, Can Resp J. 20(5):335-8, 2013.
59.Ryerson CJ , Cayou C , Topp F , Hilling L , Camp PG , Wilcox PG , Khalil N , Collard HR , Garvey C, “Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study.”, Resp Medicine 108(1):203-210, 2014.
60.Pandey AK, Wilcox P, O’ Brien J, Ellis J, Brown J, Leipsic J. Significance of various pulmonary and extrapulmonary abnormalities on HRCT of the chest in scleroderma lung. Indian J Radiol Imaging 23 (4) 304-307, 2013
61.Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, Collard HR, Ryerson CJ. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: A systematic review. Chest 146(2):422-36, 2014.
62.Quon BS, Ngan DA, Wilcox PG, Man SFP, Sin DD. sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis PLos One 9(2):e89341, 2014.
63.Jen R, Biagioni B, Wilcox P, Schellenberg B. Treatment of nonspecific interstitial pneumonia (NSIP) with Rituximab in a patient with Hyper-IgM Syndromes (HIGM), Chest, 145(3 Supppl):218A, 2014.
64.Quon BS. Schaeffer MR. Molgat-Seon Y. Wilkie SS. Wilcox PG. Guenette JA. Physiological mechanisms of dyspnea relief following ivacaftor in cystic fibrosis: A case report. Respiratory Physiology & Neurobiology. 205:105-8, 2015
65.Zlosnik JE, Zhou G , Brant R , Henry DA , Hird TJ , Mahenthiralingam E , Chilvers MA , Wilcox P , Speert DP, Burkholderia spp. Infection in Cystic Fibrosis Patients in British Columbia, Canada: 30 Years’ Experience. Ann Amer Thor Soc, 2014 Dec 5 [Epub ahead of print 25474359].
66.Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2014 Oct 30 [Epub ahead of print 25453872]
67.Ryerson CJ, O’Connor D, Schooley F, Hague CJ, Murphy D, Leipsic J, Dunne J, Wilcox PG. Application of IPF mortality prediction tools to scleroderma-associated interstitial lung disease. Chest; 2015 Nov;148(5):1268-75.
68.Leung SC, Churg AM, Leipsic JA, Levy RD, Wilcox PG, Ryerson CJ. Unclassifiable interstitial lung disease: An unresolved diagnostic dilemma. Respirology Case Reports; 2015 Sep;3(3):85-8.
69.Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. The Canadian Registry for Pulmonary Fibrosis. Canadian Respiratory Journal; e-published November 2, 2015
70.Valerie Waters; Stanojevic Sanja; Nicole Sonneveld; Michelle Klingel; Hartmut Grasemann; Yvonne Yau; Elizabeth Tullis; Pearce Wilcox; Andreas Freitag; Mark Chilvers; Felix Ratjen Factors Associated with Response to Treatment of Pulmonary Exacerbations in Cystic Fibrosis Patients Journal of Cystic Fibrosis 14 755-62 2015
71.James E. A. Zlosnik1 , Guohai Zhou2 , Rollin Brant2 , Deborah A. Henry1 , Trevor J. Hird1 , Eshwar Mahenthiralingam3 ,Mark A. Chilvers4 , Pearce Wilcox5 , and David P. Speert1Burkholderia spp. Infection in Cystic Fibrosis Patients in British Columbia, Canada: 30 Years’ Experience Ann Amer Thor Soc 12 70-8 2015
72.Valerie Waters; Stanojevic Sanja; Nicole Sonneveld; Michelle Klingel; Hartmut Grasemann; Yvonne Yau; Elizabeth Tullis; Pearce Wilcox; Andreas Freitag; Mark Chilvers; Felix Ratjen Randomized Controlled Trial Of Biofilm Antimicrobial Susceptibility Testing In Cystic Fibrosis Patients Journal of Cystic Fibrosis 14 262-6 2015
73.Kirkpatrick G, Winstone T, Wilcox P, Van Eeden S.Pulmonary hemorrhage in cryoglobulinemia. Can Respir J. 2014 Dec 10. pii: 16582.
74.Payanden J, McGillivray B, McCauley, Wilcox P, Swiston J, Lehman A A Clinical Classification Scheme for Tracheobronchomegally (Mournier- Kyhn Syndrome) Lung 193 815-22 2015
75.Kirkpatrick G, Winstone T, Wilcox P, VanEeden S Pulmonary Hemmorhage in Cryoglobulinemia CRJ 22 13-5 2015
76.Roberts JM, Wilcox PG, Quon BS. Evaluating adult cystic fibrosis care in British Columbia: Disparities in access to a multidisciplinary treatment centre. Can Respir J 2015. [Epub ahead of print PMID 26529514]
77.Quon BS, Wilkie SS, Molgat-Seon Y, Schaeffer MR, Ramsook AH, Wilcox PG, Guenette JA. Cardiopulmonary and sensory responses to exercise in adults with mild cystic fibrosis. J Appl Physiol 2015. [Epub ahead of print PMID 26429870]
78.Habib AR, Quon BS, Alsaleh S, Manj J, Buxton JA, Singer J, Wilcox PG, Javer AR. Sinonasal Outcomes Test-22 as a Tool to Identify Chronic Rhinosinusitis in Adults with Cystic Fibrosis. Int Forum Allergy Rhinol 2015. [Epub ahead of print PMID 26228968
79.Quon BS, Wilcox PG. A New Era of Personalized Medicine for CF – at last! Can Respir J 2015; 22(5):257-60. PMID 26083544
80.Habib AR, Buxton JA, Singer J, Wilcox PG, Javer AR, Quon BS. Association between Chronic Rhinosinusitis and Health-Related Quality of Life in Adults with Cystic Fibrosis. Ann Am Thorac Soc 2015; 12(8): 1163-9. PMID 26011015
81.Quon BS, Lai LY, Ng R, Hollander Z, Wilcox PG, Tebbutt SJ, Sin DD. Discovery of Novel Plasma Protein Biomarkers to Predict Imminent Cystic Fibrosis Exacerbations Using Multiple Reaction Monitoring Mass Spectrometry. Thorax 2015. [Epub ahead of print PMID 25777587]
82.Quon BS, Schaeffer MR, Molgat-Seon Y, Wilkie SS, Wilcox PG, Guenette JA. Physiological mechanisms of dyspnea relief following ivacaftor in cystic fibrosis: A case report. Respir Physiol Neurobiol 2015; 205:105-108, 2014. PMID 25447681

83.Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. The Canadian Registry for Pulmonary Fibrosis. Canadian Respiratory Journal; 2016: 3562923.
84.Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O’Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Moran-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. High Oxygen delivery to Preserve Exercise capacity in IPF patients treated with nintedanib: Methodology of the HOPE-IPF study. Annals of the American Thoracic Society; 2016 Sep 1; 13(9): 1640-7.
85.Milne K, Kwan JM, Guler S, Winstone TA, Le A, Khalil N, Camp PG, Wilcox PG, Ryerson CJ. Prevalence of frailty in fibrotic interstitial lung disease. Respirology; e-published Nov 9, 2016.
86.Sharma A, Kirkpatrick G, Chen V, Skolnik K, Hollander Z, Wilcox PG, Quon BS. Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations. PLoS One 2017. [Accepted Jan 11, 2017
87.Lin AH, Kendrick J, Wilcox PG, Quon BS. Patient Knowledge and Medication Adherence in Adults with Cystic Fibrosis. Patient Preference and Adherence 2017. [Accepted Jan 25, 2017]
88.Skolnik K, Levy RD, Wilcox PG, Quon BS. Coronary artery disease in cystic fibrosis: an emerging concern. Journal of Cystic Fibrosis 2016; 15(6):e70-e71. [PMID 27751792
89.Quon BS, Wilkie SS, Ramsook AH, Schaeffer MR, Puyat JH, Wilcox PG, Guenette JA. Qualitative dimensions of exertional dyspnea in adults with cystic fibrosis. J Appl Physiol 2016. [Epub ahead of print PMID 27311438]
90.du Plessis J, Fernandes S, Jamal R, Camp PG, Guenette, JA, Schaeffer M, Wilcox PG, Ryerson CJ. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than chronic obstructive pulmonary disease. Respirology; e-published Nov 28, 2017.
91.Dhillon SS, Levy RD, Wilcox PG, Guenette JA, Quon BS, Ryerson CJ, Camp PG. Physical activity measurement accuracy in advanced chronic lung disease. Canadian Journal of Respiratory, Critical Care and Sleep Medicine; in press
92.Guler S, Kwan JM, Winstone TA, Milne KM, Dunne JV, Wilcox PG, Ryerson CJ. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respiratory Medicine. 2017 Aug; 129:1-7.
93.Cheng J, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology; 2017 Nov;22(8):1592-1597.
Accompanying editorial (PMID: 28677213)
94.Milne K, Kwan JM, Guler S, Winstone TA, Le A, Khalil N, Camp PG, Wilcox PG, Ryerson CJ. Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology; 2017 May; 22(4): 728-734.
95.Sharma A, Kirkpatrick G, Chen V, Skolnik K, Hollander Z, Wilcox P, Quon BS Clinical Utility of C-reactive protein to predict response during cystic fibrosis pulmonary exacerbations PLoS One 12(2) e0171229 2017
96.Lin AH, Kendrick JG, Wilcox PG, Quon BS Patient Knowledge and pulmonary medication in adult patients with cystic fibrosis Patient preference and Adherence 11:691-8, 2017
97.Winstone TA, Hague CJ, Soon J, Sulaiman N, Murphy D, Leipsic J, Dunne J, Wilcox PG, Ryerson CJ. Esophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. Respirology. 2018 Oct; 23(10): 921-6.
98.du Plessis J, Fernandes S, Jamal R, Camp PG, Guenette, JA, Schaeffer M, Wilcox PG, Ryerson CJ. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than chronic obstructive pulmonary disease. Respirology. 2018 Apr:23(4):392-8.
99.Dhillon SS, Levy RD, Wilcox PG, Guenette JA, Quon BS, Ryerson CJ, Camp PG. Physical activity measurement accuracy in advanced chronic lung disease. Canadian Journal of Respiratory, Critical Care and Sleep Medicine; in press
100.Guler SA, Winstone TA, Murphy D, Hague CJ, Soon J, Sulaiman N, Li KH, James Dunne, MD, Wilcox PG, Ryerson, CJ. Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Annals of the American Thoracic Society. e-published Sep 6, 2018
101.Roberts JM, Dai LY, Hollander Z, Ng RT, Tebbutt SJ, Wilcox PG, Sin DD, Quon BS. Multiple Reaction Monitoring Mass Spectrometry to Identify Novel Plasma Protein Biomarkers of Treatment Response in Cystic Fibrosis Pulmonary Exacerbations. Journal of Cystic Fibrosis 2018. [PMID: 29174082]
102.Middleton MA; Layeghifard M; Klingel M; Stanojevic S; Yau YCW; Zlosnik JEA; Coriati A; Ratjen FA; Tullis ED; Stephenson A; Wilcox P; Freitag A; Chilvers M; McKinney M; Lavoie A; Wang PW; Guttman DS; Waters VJ. Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population Annals of the American Thoracic Society. 15(7):827-836, 2018 Jul
103.Roberts JM; Dai DLY; Hollander Z; Ng RT; Tebbutt SJ; Wilcox PG; Sin DD; Quon BS. Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations.
Journal of Cystic Fibrosis. 17(3):333-340, 2018 May
104.Dougherty DH; Kwakkenbos L; Carrier ME; Salazar G; Assassi S; Baron M; Bartlett SJ; Furst DE; Gottesman K; van den Hoogen F; Malcarne VL; Mouthon L; Nielson WR; Poiraudeau S; Sauve M; Boire G; Bruns A; Chung L; Denton C; Dunne JV; Fortin ; Frech T; Gill A; Gordon J; Herrick AL; Hinchcliff M; Hudson M; Johnson SR; Jones N; Kafaja S; Larche M; Manning J; Pope J; Spiera R; Steen V; Sutton E; Thorne C; Wilcox P; Thombs BD; Mayes MD; SPIN Investigators. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford). 57(9):1623-1631, 2018 09 01

Non Refereed Publications

(a) Journals

1.Wilcox PG and Pardy RL. Exercise testing in the assessment of the patient with dyspnea.a) Normal and abnormal exercise physiology. Current Cardiology. 12:18-25, 1988.
2.Wilcox PG and Pardy RL. Exercise testing in the assessment of the patient with dyspnea. b) A diagnostic approach. Current Cardiology. 3:13-25, 1988.
3.Paré PD, Pardy RL, Wilcox PG. Nonpulmonary causes of ventilatory respiratory failure. Rev Inst Nal Enf Resp Mex. 3(1):46-50, 1991.
4.Bryce EA, Barteluk RL, Noble MA, Wilcox PG. Community acquired Legionella Micdadei pneumonia presenting as acid fast bacilli in sputum. CMNEEJ. 13(12)89-96, 1991.
5.Ferguson K, Wilcox P. Home ventilation in adults. BCMJ. 35:585-587, 1993.
6.Reid D, Jones M, Chung F, Wagar B, Road J, Wilcox P. Intermittent nasal positive pressure ventilation in patients with chronic obstructive lung disease. 1997 Eur Respir J.
7.Harding G, Davant R, Wilcox PG, et al. The Antibiotic puzzle. 2002.
8.Co Editor Cystic Fibrosis News Network Lind Publishing quarterly 2008- 2016.

(c) Other

Grieve J et al Canadian Consensus Statement on Aerosolized Antibiotics in Cystic Fibrosis Canadian Cystic Fibrosis Foundation 2006

Abstracts

1.Wilcox P, Dickson RI, Blokmanis A, and Fleetham J. Treatment of obstructive sleep apnea by uvulopalatopharyngoplasty: long-term experience. Am Rev Respir Dis. 133:A233, 1986.
2.Wilcox P, Lowe AA, and Fleetham JA. 3-D reconstructions of tongue and airway in obstructive sleep apnea. Am Rev Respir Dis 133:A147, 1986.
3.Wilcox P and Pardy RL. Comparison of diaphragmatic relaxation rate (RRdi) after voluntary sniffs and unilateral phrenic stimulation. Am Rev Respir Dis. 133:A249, 1986.
4.Wilcox P, Coppin C, Stein H, Chalmers A, Huang S, Paré P, Pardy RL. Phrenic nerve function, inspiratory muscle weakness and systemic lupus erythematosus (SLE). Clin Invest Med. A154, 1986.
5.Wilcox P, Baile E, Paré P, Pardy RL. Phrenic nerve function and its relationship to atelectasis following coronary bypass (CAB). Am Rev Respir Dis. A355, 1987.
6.Wilcox P, Bassett A, Jones B, Fleetham J. Respiratory dysrhythmias in awake and sleep patients with tardive dyskinesia. Presented American Psychiatry Association Meeting, 1987.
7.Wilcox P, Stein H, Clarke S, Paré P, Pardy RL. Etiology of respiratory muscle weakness in systemic lupus erythematosus. Presented American College of Chest Physicians Meeting, 1987.
8.Wilcox P, Road JD, Paré PD, Fleetham JA. Inspiratory muscle function during obstructive sleep apnea. Am Rev Respir Dis. 137:A74, 1988.
9.Wilcox P, Hards J, Bressler B, Pardy RL. Pathological changes and contractile properties of the diaphragm in corticosteroid myopathy in hamsters. Comparison to peripheral muscle. Am Rev Respir Dis. 137:A320, 1988.
10.Wilcox P, Andolfatto G, Pardy RL. Long-term follow-up of symptoms, pulmonary function, respirstory muscle strength and exercise performance after botulism. Am Rev Respir Dis. 137, 1988.
11.McElvaney G, Fairbarn MS, Wilcox PG, Pardy RL. Comparison between 2-2-minute incremental threshold loading and maximal loading as tests of respiratory muscle endurance. Am Rev Respir Dis. 137:A514, 1988.
12.Blackie S, Fairbarn MS, Morrison N, Wilcox P, McElvaney G, Pardy R. Maximal oxygen uptake (VO2 max) and power (Wmax) for a cycle ergometer test: Normal values in subjects over 55 years of age. Am Rev Respir Dis. 137:A335, 1988.
13.McElvaney G, Blackie S, Morrison N, Wilcox P, Fairbarn MS, Pardy RL. Maximal static respiratory pressures in the normal elderly. Am Rev Respir Dis. 137:A447, 1988.
14.McElvaney G, Blackie S, Morrison N, Fairbarn MS, Wilcox P, Pardy RL. Cardiac output at rest and in exercise in elderly. Am Rev Respir Dis. 137:A123, 1988.
15.Dubeta KR, Pijl S, Clelland J, Wilcox P, Davison R, Chan R. Otolaryngologic and respiratory manifestations of botulism – a multidisciplinary study. Canadian Society Otolaryngology Head and Neck Surgery, June 1988.
16.McElvaney G, Wilcox P, Wilkilns GE, Fairbarn MS, Hilliam C, Paré PD, Pardy RL. Does respiratory muscle (RM) weakness cause increased dyspnea in hyperthyroid subjects? Am Rev Respir Dis. 139:A87, 1989.
17.Wilcox PG, Morrison NJ, Pardy RL. Progression of recovery post-botulism. Am Rev Respir Dis. 139:A163, 1989.
18.Wilcox PG, Paré PD, Pardy RL. Thawing after phrenic nerve frostbite. Am Rev Respir Dis. 139:A345, 1989.
19.Cala SJ, Wilcox P, Edyvean J, and Engel LA. Oxygen cost of breathing (VO2resp) during inspiratory resistive or elastic loading. Am Rev Respir Dis. 139:A347, 1989.
20.Ryan CFP, Road JD, Wilcox PG. Nocturnal assisted ventilation improves inspiratory muscle strength but not endurance in hypercapnic ventilatory failure. Am Rev Respir Dis. 141:720 A, 1990.
21.Wilcox PG, Blackie S, Clarke S, Pardy RL. Twitch PDI: An effort independent measurement of diaphragmatic strength? Am Rev Respir Dis. 141:A720, 1990.
22.Blackie SP, Fairbarn MS, Wilcox PG, McElvaney GW, Morrison NJ, Wiggs BR, Pardy RL. Sex and age influence breathing patterns during exercise. Am Rev Respir Dis. 141:A122, 1990.
23.Wakai Y, Wilcox P, Cooper J, Walley K and Road J. The effect of tumor necrosis factor (TNF) on diaphragmatic contractility in anesthetized dogs. Am Rev Respir Dis. 143:A560, 1991.
24.Alexander DJ, Wakai Y, Road J and Wilcox PG. Bi-level positive airway pressure (BIPAP) for ventilatory muscle support in patients with chest wall and neuromuscular disorders. Am Rev Respir Dis. 143:A166, 1991.
25.Wilcox PG, Osborne S, Bressler B. Diaphragmatic contractility is impaired by monocyte inflammatory secretory products. Am Rev Respir Dis. 143:A236, 1991.
26.Pardy RL, Fairbarn MS, Blackie SP, McElvaney MC, Wilcox PG, Morrison NJ. Ventilatory and breathing pattern in normal men and women in exercise. Am Rev Respir Dis. 143:A174, 1991.
27.Buckle P, Alexander D, Road JD, Ryan CF, Oger J, Wilcox PG. Ventilatory muscle endurance as an indicator of muscle weakness in myasthenia gravis. Am Rev Respir Dis. 145:A157, 1992.
28.Wilcox P, Bressler B. Effects of tumour necrosis factor ” on in vitro hamster diaphragm contractility. Am Rev Respir Dis. 145:A457, 1992.
29.Hebert P, Cooper J, Wakai Y, Wilcox P, Road J, Walley K. Early decrease in left ventricular contractility after TNF” infusion. Am Rev Respir Dis. 145:A74, 1992.
30.Turner SPD, McKenzie DC, Coutts KC, Wilcox PG, Jespersen DK, Cooper TK. The effects of intense exercise on DLCO and %SaO2 in competition athletes. Am Physiol Soc, 1992.
31.Jiang TX, Cairns A, Road JD, and Wilcox PG. Inspiratory muscle activation during lung inflation in vagotomized rabbits. Am Rev Respir Dis. 147(4):A704, 1993.
32.Jiang TX, Cairns A, Road JD and Wilcox PG. Clenbuterol does not prevent dexamethasone induced diaphragm dysfunction. Am J Respir Crit Care Med. 149:A274, 1994.
33.Milliken C, Bressler B, and Wilcox PG. Tumor necrosis factor produces a membrane dependent reduction in diaphragm contractility. Am J Respir Crit Care Med. 149:A272, 1994.
34.Jiang TX, Wilcox PG, Belcastro, AN and Road JD. Effects of lipopolysaccharide on diaphragm and limb muscle atrophy induced by denervation in rat. Am J Respir Crit Care Med. 151: A585, 1995.
35.Jiang TX, Wilcox PG, Cairns A, Belcastro AN and Road JD. High energy phosphates in diaphragm and limb muscles of denervated and endotoxemic rats. Am J Respir Crit Care Med. 151:A584, 1995.
36.Milliken C, Bressler B and Wilcox PG. Ventilatory muscle involvement in a murine model of muscular dystrophy. Am J Respir Crit Care Med. 151: A586, 1995.
37.Frangolais D, Nakielna B, Wilcox P. Case control study evaluating the effects of pregnancy on respiratory function in cystic fibrosis. Ped Pulm. 12: A392, 1995.
38.Nakielna E, Hopkins J, Wilcox P. Venous Thrombosis: a complication of venous access devices in cystic fibrosis patients. Ped Pulm 12:A370, 1995.
39.Jiang TX, Road J, Wilcox P. Effects of the ß agonist clenbuterol on dexamethasowe induced diaphragm atrophy in rabbit. The Royal College of Physicians and Surgeons of Canada Meeting, September 1995.
40.Jiang TX, Wilcox PG. Effects of tumour necrosis factor alpha on hamster diaphragm contractility is mediated by nitric oxide. Am J Respir Crit Care Med. 153:A439, 1996.
41.Jiang TX, Wilcox PG. Diaphragm injury induced by inspiratory resistive loading in the rabbit. Am J Respir Crit Care Med. 153:A296, 1996.
42.Frangolias D, Raboud JM, Nakielna EM, Wilcox PG. Effect of burkholderia cepacia acquisition on clinical courses in cystic fibrosis: a case control study. IS Med Sci. 32:S171, 1996.
43.Chaun H, Nakielna EM, Wilcox PG. Endoscopic findings in adult cystic fibrosis patients investigated for upper gastrointestinal symptoms. Cdn Digestive Diseases Wk 1997.
44.Frangolias D, Rae S, Raboud JM, Corey M, Tullis E, Nakielna EM, Mahenthiralingan E, Speert DP, Wilcox PG. Effects of burkholderia cepacia acquisition and genotype on clinical coursre in cystic fibrosis. Am J Respir Crit Care Med. 155:A644, 1997.
45.Partovin D, Fradet G, Cook RC, Lambert N, Prior J, Ostrow P, Wilcox P, Levy R. Determinants of bone density following lung transplantation. Submitted North American CF Conference. 1997.
46.Frangolias D, Wilcox PG. Predicting Normal Oxygen Desaturation in Cystic Fibrosis from Clinical, Spirometric and Exercise Parameters. Am J Respir Crit Care Med. 157:A128, 1998.
47.Frangolias D, Mahenthiralingam E, Speert D, D’Yachkova U, Wilson WM, Davidson G, Berthiaume Y, Campbell M, Henry D, Hennessey R, Lavallee J, Wilcox PG. Burkholderia cepacia in cystic fibrosis: Effects of genotype on clinical course. Am J Respir Crit Care Med. 157:A129, 1998.
48.Frangolias D, Sandford AJ, Wilcox PG, Corey M, Sweezey N, Tullis E, Davidson G, Paré PD. Alpha-1-antitrypsin levels during pulmonary exacerbations in cystic fibrosis. Submitted for presentation at the 1998 North American Cystic Fibrosis Conference in Montreal. Pediatric Pulmonology. 17 suppl:329-330, 1998.
49.Frangolias DD, Holloway CL, Vedal S and Wilcox PG. Predicting disability in cystic fibrosis. Am J Respir Crit Care Med. 159:A684, 1999.
50.Frangolias DD, Holloway CL, Vedal S, Wilcox PG. Role of pulmonary function and cardiopulmonary exercise testing in predicting work impairment/disability in cystic fibrosis. Pediatric Pulmonology. 19 suppl.: 281, 1999.
51.Stuart IB, Shield W, Frangolias DD, Wilcox PG and MacKenzie DC. The affect of nitric oxide on pulmonary gas exchange and exercise capacity in patients with cystic fibrosis. Slide presentation at the Annual Conference of the Canadian Society of Exercise Physiology, Toronto, ON, October 1999. Canadian Journal of Applied Physiology. 24 suppl: A33, 1999.
52.Frangolias DD, Nakielna EM, Wilcox PG. Limiting factors for maximal exercise in cystic fibrosis patients. XIII International Cystic Fibrosis Congress, Stockholm, 2000.
53.Nakielna B, Lawson L, Wilcox P. Methicillin resistant staph aureus (MRSA) in canadian CF patients – prevalence and management strategies. XIII International CF Conference, Stockholm, 2000.
54.Frangolias D, Paré P, Kendler D, Prior J, Wilcox P. Osteoporosis in cystic fibrosis: pathogenesis and clinical features. Am J Respir Crit Care Med. 163(5): A89, 2001.
55.Frangolias DD, Ruan J, Wilcox PG, Berthiaume Y, Davidson G, Corey M, Tullis E, Zielenski J, Wilson WM, Freitag A, Sandford A, Pare PD. Alpha-1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Pediatric Pulmonology. 22 suppl: 217, 2001.
56.Frangolias DD, Ruan J, Wilcox PG, Berthiaume Y, Davidson G, Wilson WM, Freitag A, Pare PD, Sandford AJ. Association of deficiency alleles of the mannose binding lectin gene with pulmonary disease severity in cystic fibrosis. Am J Respir Crit Care Med. 165(8): A803, 2002.
57.Frangolias DD, Ruan J, Kareco T, Davidson AGF, Hennessey R, Freitag A, Pedder L, Wong L, Berthiaume Y, Wilcox PG, Pare PD, Sandford AJ. Innate immunity genes as modifier genes in pulmonary disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2003
58.Tullis E, Aaron S, Allard C, Bertiaume Y, Cantin A, Cherutti JF, Corey M, King M, Ralston I, Speert D, Wilcox P. Randomized double blind placebo controlled study of the effect of aerosolized low molecular weight dextran on pulmonary function in adults with cystic fibrosis. Pediatric Pulmonology. Suppl, 2003.
59.Frangolias D, Woods R, Davidson G, Speert D, Wong L, Hennessy R, Freitag A, Bertiaume Y, Waters I, Wilcox P, Colonization with B. cepacia complex genomovar III in cystic fibrosis is associated with more severe pulmonary disease progression. Pediatric Pulmonology. 2003
60.Frangolais D, Ruan J, Pare P, Woods R, Davidson G, Wong L, Wilcox P, Speert D. Sandford A. Investigations of the variants of the mannose binding lectin and of the pulmonary surfactant A1, A2, and D genes as candidate modifier genes of pulmonary disease severity in cystic fibrosis. Paediatric Pulmonology. suppl 2003.
61.Phillips P, Bonner S, Galaric N, Bai T, Wilcox P, O’Shaughnessy M, Montaner J. Non tuberculous mycobacterial immune reconstitution syndrome in HIV infected patients: Spectrum of disease and long term follow up. Infectious Disease Society of North America Meeting. 2004
62.Davidson W, Sin D, Wilcox P, Attridge S, Bai T. A Comparison of the Leister Cough Questionnaire with the St George’s Respiratory Questionnaire in the Evaluation of the Treatment Response in Patients with Chronic Cough. Am J Respir Crit Care Med. 2005
63.Davidson W, Wilcox P, Bai T. Clinical utility of induced sputum in the Investigation of chronic cough. Am J Respir Crit Care Med. 2006
64.Tan A, van Eeden S, Wilcox P. Systemic inflammation in cystic fibrosis. Pediatric Pulmonology. 30 suppl: 257, 2007.
65.Choi J, Wilcox P, Dunne J. Scleroderma related pulmonary hypertension: A case series and review of the literature. Eur Respir J. 30 suppl: 2007.
66.Vandemheen K, Oconnor A, Bell S, Freitag A, Bye P, Jearnneret A, Bertiaume Y, Brown N, Wilcox P, Ryan G, Brager N, Rabin H, Jackson M, Paterson N, Middleton P, Poirer C, Tullis E, Aaron S Randomized Controlled Trial of a Decision Aid for Cystic Fibrosis Patients Considering Referral for Lung Transplantation Pediatric Pulmonology 2008 31 suppl 542.
67.Quon BS, Reid JD, Wong PHG, Wilcox PG, Javir A, Wilson JM, Levy RD. University of British Columbia – Vancouver.CA Burkholderia gladioli – a predictor of poor outcome in cystic fibrosis patients who receive lung transplants? 2009 American Thoracic Society Mtg
68.James E. A. Zlosnik, Deborah A. Henry, Esh Mahenthiralingam, Trevor J. Hird, A. George F. Davidson, Pearce Wilcox, Mark Chilvers and David P. Speert 30 Years of Burkholderia cepacia complex infections in Vancouver and British Columbia, from 1981 – 2011 Pediatric Pulmonology 35 336 2012.
69.Lee KM, MacDiarmid P, Shalansky S, Wilcox P The use of self administered medicinal cannabis for Cystic Fibrosis symptom management: patient reported experiences Pediatric Pulmonology 35 579 2012
70.Ryerson CJ, Cayou C, Topp F, Hilling L, Camp P, Wilcox PG, Khalil N, Garvey CM, Collard HR, “Pulmonary Rehabilitation Improves Long-Term Quality Of Life In Patients With Interstitial Lung Disease” Abstract American Thoracic Society Annual Meeting Am J Respir Crit Care Med 187;2013:A5955″ Abstract
71.Ryerson CJ, Topp F, Cayou C, Hilling L, Pamp P, Khalil N, Wilcox PG, Collard HR, Garvey CM, “A Low Baseline 6MWD Predicts Greater Improvement From Pulmonary Rehabilitation In Interstitial Lung Disease” Abstract Am J Respir Crit Care Med 187;2013:A5955″ Abstract
72.Kendrick J, Quon BS, Wilcox PG. Abstract 399. Evaluation of Response and Adherence to Tobramycin Inhalation Powder. North American Cystic Fibrosis Conference, October 2013. Pediatric Pulmonology 2013 (Supplement 36); A 221
73.Quon BS, Ngan D, Wilcox PG, Man SF, Sin DD. Abstract 221. Plasma Soluble Cluster of Differentiation 14 (sCD14) as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis. North American Cystic Fibrosis Conference, October 2013. Pediatric Pulmonology 2013 (Supplement 36); page 284
74.Shoki AH, Mayer-Hamblett N, Wicox P, Sin D, Quon BS. Systematic Review of Blood Biomarkers I Cystic Fibrosis Pulmonary Exacerbations. North American Cystic Fibrosis Conference, October 2013. Pediatric Pulmonology A218.
75.Winstone TA, Assayag D, Wilcox PG, Dunne J, Hague CJ, Leipsic J, Collard HR, Ryerson CJ. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: A systematic review. Vancouver Heart and Lung FEST Scientific Symposium, Vancouver, 2014.
76.Cox G, Ryerson CJ, Wilcox PG. Survey of management of IPF in Canada. International Colloquium on Lung and Airways Fibrosis, Mont Tremblant, Canada, 2014.
77.Cox G, Ryerson CJ, Wilcox PG. Survey of management of IPF in Canada. European Respiratory Society, Munich, Germany, 2014.
78.Lin AH, Kendrick J, Wilcox PG, Quon BS. (2014). Patient Knowledge and Medication Adherence in Adults with Cystic Fibrosis. North American Cystic Fibrosis Conference. Pediatric Pulmonology (Supplement 38); page 437.
79.Quon BS, Dai L, Hollander Z, Wilcox PG, Tebbutt S, Sin DD. (2014). Plasma Protein Biomarkers to Prognose Short-term CF Pulmonary Exacerbation Risk. North American Cystic Fibrosis Conference. Pediatric Pulmonology (Supplement 38); page 308
80.Habib A.R., Manji J., Wilcox P., Javer A.R., Buxton J., Quon BS. Systematic review of socio-demographic factors and clinical characteristics associated with the health-related quality of life among adolescents and adults with cystic fibrosis. North American Cystic Fibrosis Conference. Pediatric Pulmonology (Supplement 38); page 439.
81.Habib A.R., Quon BS, Wilcox P., Singer J., Javer A.R., Buxton J. Evaluating the impact of chronic rhinosinusitis on the health-related quality of life among adults with cystic fibrosis. North American Cystic Fibrosis Conference. Pediatric Pulmonology (Supplement 38); page 439. 2014
82.Waters VJ, Ratjen F, Tullis E, WilcoxPG, Freitag A, Chilvers M, Grasemann H, Zlosnick J, Speert D, Corey M, Stanjovic S, Matakas L, Leahy T, Shih S, Yau Y Randomized Controlled Trial of Biofilm Antimicrobial Susceptibility Testing in Pulmonary Exacerbations in Cystic Fibrosis Patients with Chronic Pseudomonas Aeruginosa Infection A 287 Pediatric Pulmonary (S38) 2014
83.Ratjen F, Stanojevic S, Sonneveld N, Grasemann H, Tullis E, Wilcox PG, Freitag A, Chilvers M, Waters VJ Predictors of Response to Antibiotic Treatment of Pulmonary Exacerbations in Cystic Fibrosis Patients A387 Ped Pulmonology S38 2014
84.Dhillon SS, Levy RD, Wilcox PG, Guenette JA, Quon BS, Ryerson CJ, Camp PG. Physical Activity Measurement accuracy in Advanced Chronic Lung Disease. American Thoracic Society International Conference, Denver, 2015.
85.Milne K, Kwan J, Winston TA, Wilcox PG, Ryerson CJ. Prevalence of frailty in fibrotic interstitial lung disease. Pulmonary Fibrosis Summit, Washington 2015.
86.Winstone TA, Kwan JM, Milne K, Schooley F, Dunne J, Wilcox PG, Ryerson CJ. Frailty is common and associated with dyspnea severity in scleroderma-associated interstitial lung disease. Pulmonary Fibrosis Summit, Washington 2015.
87.Dhillon SS, Levy RD, Wilcox PG, Guenette JA, Quon BS, Ryerson CJ, and Camp PG. Physical activity measurement in advanced chronic lung disease. Presented at the International Society for Heart and Lung Transplantation Annual Meeting, Nice, France, April 15-18, 2015. The Journal of Heart and Lung Transplantation. 2015;34(4):S72
88.Optimizing the Management of Asthma in Primary Care Ronald F. Grossman, MD1, Alan G. Kaplan, MD2, Ronald Olivenstein, MD3, Pearce G. Wilcox, MD4, Marsha R. Haynes, PhD5 accepted American Thoracic Society meeting 2016
89.Quon B, Wilkie S, Molgat-Seon Y, Schaeffer M, Ramsook A, Wilcox P, Guenette J Cardiopulmonary Fitness is Preserved in Adults with Mild CF Paed Pulmon 50 S41 130 2015
90.Sharma A, Wilcox P, Quon B Early Changes in Serum C-Reactive Protein Predict Treatment Failure During Cystic Fibrosis Pulmonary Exacerbations Paed Pulmon 50 S41 254 2015
91.Ho A, Su V, Espinosa B, Lilliquist A, Chilvers M, Quon B, Wilcox P, Zlosnick J Evaluation of Burkholderia SPP Eradication Eradicadication in Cystic Fibrosis (CF) Patients Paed Pulmon 50 S41 291 2015
92.Quon B, Wilcox P, Cho E, Chilvers M, Kendrick J Medication Adherence and Longitudinal Pulmonary Outcomes in Children and Adults with CF Paed Pulmon 50 S41 4482015
93.BertiaumeY,ChilversM, WilcoxP, RatjenF, Hodgkins P, O’Sullivan A Burden of Illness in Cystic Fibrosis Patients in Canada who are Homozygous for the F508del- CFTR Mutation Pediatric Pulmonology
94.Du Plessis J, Fernandes S, Jamal R, Camp P, Johannseon K, Schaeffer M, Wilcox P, Guenette J, Ryerson C Exertional Hypoxemia is more severe in Fibrotic Interstitial Lung Disease than COPD American Thoracic Society meeting May, 2016
95.Winstone TA, Kwan JM, Milne K, Schooley F, Dunne J, Wilcox PG, Ryerson CJ. Frailty is common and associated with dyspnea severity in patients with systemic sclerosis-associated interstitial lung disease. Heart and Lung FEST Scientific Symposium, Vancouver, 2016.
96.Milne K, Kwan J, Winston TA, Wilcox PG, Ryerson CJ. Prevalence of frailty in fibrotic interstitial lung disease. American Thoracic Society International Conference, San Francisco, 2016.
97.Winstone TA, Kwan JM, Milne K, Schooley F, Dunne J, Wilcox PG, Ryerson CJ. Frailty is common and associated with dyspnea severity in patients with systemic sclerosis-associated interstitial lung disease. American Thoracic Society International Conference, San Francisco, 2016.
98.Winstone TA, Hague CJ, Murphy D, Leipsic J, Dunne J, Wilcox, PG, Ryerson CJ. Rate of progression in short-term and long-term survivors with systemic sclerosis-associated interstitial lung disease. International Colloquium for Lung and Airway Fibrosis, Dublin, Ireland, 2016.
99.Winstone TA, Hague CJ, Murphy D, Leipsic J, Dunne J, Wilcox, PG, Ryerson CJ. Esophageal diameter is associated with systemic sclerosis-associated interstitial lung disease severity and progression. International Colloquium for Lung and Airway Fibrosis, Dublin, Ireland, 2016
100.Berthiaume, Y.; Chilvers, M.; Wilcox, P.; Ratjen, F.;Hodgkins, P; O’Sullivan, A.. Burden of Ilness In CF Patients In Canada Who Are Homozygous For the F508DEL-CFTR Gene Mutation Paediatr Pulmonology 51 S45 2016
101.Roberts, J.M.; Le, A.; Dai, D.; Hollander, Z.; Flores, E. Wilcox, P; Quon, B.S. Blood-Based Biomarkers to Predict CF Exacerbation Treatment Response Paediat Pulmonology 51 S239 2016
102.Skolnik, K.; Levy, R.; Wilcox, P.; Quon, B.S.Prevalence of Coronary Artery Disease and Left Ventricular Dysfunction in Cystic Fibrosis Patients Undergoing Lung Transplant Evaluation Paediatr Pulmonology 51 S45 2016
103.Du Plessis JP, Fernandes S, Jamal R, Camp PG, Johannson KA, Schaeffer M, Wilcox PG, Guenette JA, Ryerson CJ. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than chronic obstructive pulmonary disease. American Thoracic Society International Conference, Washington DC, 2017
104.Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ. Severity, predictors, and impact of cough in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. HLI Fest, Vancouver, BC, 2017.
105.Du Plessis JP, Fernandes S, Jamal R, Camp PG, Johannson KA, Schaeffer M, Wilcox PG, Guenette JA, Ryerson CJ. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than chronic obstructive pulmonary disease. HLI Fest, Vancouver, BC, 2017
106.Middleton,M, Layeghifard,M, Klingel,M, Stanojevic,S, Yau,Y, ZlosnikJ, Coriati,A, Ratjen,F, Tullis,E, Stephenson,A, Wilcox,P, Freitag,A, Chilvers,M, McKinney,M, Lavoie,A, Wang,P, Guttman,D , Waters,V Distribution and clinical impact of clonal Pseudomonas aeruginosa infection in the Canadian cystic fibrosis population Pediatric Pulmonology 52 2017
107.Fu J, Flores E, Desai S, Wilcox PG, Quon BS. Relationship between Early and Overall Changes in CFRSD-CRISS and FEV1 during the Treatment of CF Pulmonary Exacerbations. The 2017 North American Cystic Fibrosis Conference. Pediatric Pulmonology 2017; 52: S47.
108.Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Wilcox PG, Khalil N, Shapera S, Hambly N, To T, Halayko A, Gershon AS, Cox G, Ryerson CJ. Workplace productivity in patients with connective tissue disease-associated interstitial lung disease. sHeart and Lung Health FEST, Vancouver, Canada, 2018..
109.Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Shapera S, To T, Khalil N, Wilcox PG, Cox G, Ryerson CJ. Workplace productivity in patients with fibrotic interstitial lung disease. Heart and Lung Health FEST, Vancouver, Canada, 2018.
110.Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Wilcox PG, Khalil N, Shapera S, Hambly N, To T, Halayko A, Gershon AS, Cox G, Ryerson CJ. Workplace productivity in patients with fibrotic interstitial lung disease. American Thoracic Society International Conference, San Diego, USA, 2018.
111.Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Shapera S, To T, Khalil N, Wilcox PG, Cox G, Ryerson CJ. Workplace productivity in patients with connective tissue disease-associated interstitial lung disease. American Thoracic Society International Conference, San Diego, USA, 2018
112.Guler SA, Kwan JM, Wilcox PG, Ryerson CJ. Frailty Is an Independent Predictor of Mortality in Patients with Fibrotic Interstitial Lung Disease. American Thoracic Society International Conference, San Diego, USA, 2018.
113.Fisher J, Shapera S, Algamdi M, Morisset J, Johannson KA, Fell CD, Kolb MR, Manganas H, Cox GP, Khalil N, Halayko AJ, Gershon AS, To TM, Hambly N, Sadatsafavi M, Wilcox PG, Ryerson CJ. Baseline Characteristics and Comorbidities in The CAnadian Registry for Pulmonary Fibrosis. American Thoracic Society International Conference, San Diego, USA, 2018.
114.Guler SA, Hur SA, Lear SA, Camp PG, Wilcox PG, Leung JM, Ryerson CJ. Dehydroepiandrosterone sulfate plasma levels correlate with lung function, muscle mass, and physical performance in fibrotic interstitial lung disease. European Respiratory Society International Congress, Paris, France, 2018
115.Guler SA, Kwan JM, Wilcox PG, Ryerson CJ. Frailty is an independent predictor of number and length of hospitalisations in patients with fibrotic ILD. European Respiratory Society International Congress, Paris, France, 2018.
116.Guler SA, Leung JM, Kwan JM, Wilcox PG, Ryerson CJ. The impact of chronological, cellular, and biosocial aging on survival in patients with fibrotic interstitial lung disease. International Colloquium on Lung and Airway Fibrosis, Pacific Grove, USA, 2018.
117.Sergeev V, Flores E, Kerr J, Su V, Wilcox PG, Quon BS. Rates of treatment discontinuation following the initiation of lumacaftor-ivacaftor in adults with CF: a single center experience. The 2018 North American Cystic Fibrosis Conference. Pediatric Pulmonology 2018; 53(S2): S148-456.
118.Kwong E, Chong L, Lee K, Zheng J, Wilcox PG, Quon BS. The impact of cystic fibrosis-related diabetes on health-related quality of life. The 2018 North American Cystic Fibrosis Conference. Pediatric Pulmonology 2018; 53(S2): S148-456.
119.Lee M, Hu L, Kwong E, Fu J, Flores E, Wilcox PG, Quon BS. A survey to better understand the barriers and facilitators to research participation for individuals with CF. The 2018 North American Cystic Fibrosis Conference. Pediatric Pulmonology. Pediatric Pulmonology 2018; 53(S2): S148-456.

Books

1.Al Talg A, Road J, Wilcox P. Pulmonary Function Tests in Clinical Practice. 2009, Springer Verlag Lonon.

2.Aboulouson K, Altalag A, Road J, Wilcox P. Pulmonary Function Tests in Clinical Practice Edition 2 Springer 2019

Chapters

1.Reid D, Wilcox P. Respiratory muscle rest. Seminars in Respiratory Disease. 13:22-32, 1991.
2.Wilcox PG. Cough. In: Therapeutic Choices. Gray J. ed. 2003.
3.Malhotra S, Wilcox P. Pregnancy and the cystic fibrosis patient. In: Pulmonary problems in pregnancy: Clinical and research aspects. Bourjaily G and Rosene-Montella K. ed. Springer .227-237, 2009.
4.Wilcox P. Chronic cough in adults. In: Therapeutic Choices, 7th edition, Gray J, ed. 2017
5.Leung J, Wilcox P Pulmonary Complications in Human Immunodeficiency Virus Infection Chapter Editors Decision Support Medicine digital resource for Pulmonary medicine, 2nd Edition 2019

 

 

Awards & Recognition:

1.2000 UBC Anaesthesia Master Teaching Award
2.2001 Fay R. Dirks Award for Excellence in Teaching, UBC Department of Medicine
3.2001 – 2002 UBC Department of Medicine Faculty Scholar
4.2008-2009 The Howard B Stein Master Teacher Award, UBC Department of Medicine
5.2009 UBC Department of Medicine Master Teacher Award
6.2011 St. Paul’s Hospital Mission Award Nominee
7.2012 Pharmacy Practice Award. In recognition of excellence in the Pharmacy poster presentation at the CSHP – BC Branch Annual General Meeting. BC Branch, Canadian Society of Hospital Pharmacists. Lee K, Macdiarmid P, Shalansky S, Wilcox P. The use of self-administered medicinal cannabis for cystic fibrosis symptom management: patient-reported experiences
8.2013 Dr. Pat Gill Memorial Lecture Atlantic Respirology and Critical Care Conference Halifax
Dr Raja Abboud Award for Clinical Excellence (UBC Division of Respirology) Sept 2016
CF Canada Clinical Excellence Award. 2018

Recent Grants

  • Canadian Pulmonary Fibrosis Foundation – Biological and clinical impact of sex/growth hormones and telomere length on sarcopenia and fraility in Fibrotic ILD (08/2018-present)
  • University of Alberta – The use of Fructosamine in Cystic Fibrosis Related Diabetes (CFRD) Screening and Diagnosis (10/2017-present)
  • Roche Pharmacuticals – A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interestitial Lung Disease (06/2018-present)
  • Proteostasis Therapeutics – A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Subjects with Cystic Fibrosis (2018)
  • Vertex Pharmaceuticals – A Phase 3, Open label Rollover Study to Evaluate the Safety and Efficacy of VX-661 in Combination with Ivacaftor in subjects ages 12 years and older with Cystic Fibrosis Homozygous or Heterozygous for the F508 del CFTR Mutation (2018)
  • Corbus Pharmaceuticals – A Multicentre Randomized, Double Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis (04/10/2018-present)
  • Cystic Fibrosis Foundation (US) – Prospective, Randomized, Placebo controlled trial of the efficacy and safety if inhaled nitric oxide (NO) in Cystic Fibrosis Patients Protocol#NO-CF-02E (2016-2018)
  • Proteostasis – A Multicentre, Randomized, Placebo-Controlled, Phase 1, Two-Part Study designed to assess the Safety, Tolerability, Pharmacokinetics, Food Effect and Drug-Drug Interactions of PTI-801 in subjects with Cystic Fibrosis (2017-present)
  • Vertex Pharmaceuticals – A Phase 3, Open label Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (2016-present)
  • Novoteris – Nitric Oxide in CF (2018-present)
  • CF Canada – PIPE Biomarker Study (2018-present)
  • U.S. Cystic Fibrosis Foundation Therapeutic Development Network – CF Canada Clinical Trial Network (03/2018-02/2019)
  • British Columbia Lung Association – A double-blind placebo-controlled crossover study to assess the effects of bronchodilation on dysponea, ventilator responses and exerces tolerance in adults with cystic fibrosis (09/2017-08/2019)
  • Cystic Fibrosis Canada – Genetic Epidemiology of Cystic Fibrosis (03/2016-02/2019)
  • CF Canada – Randomized controlled trial of prednisone in cystic fibrosis (CF)pulmonary exacerbations (PIPE Study) (2016-present)
  • Cystic Fibrosis Canada – External replication of a plasma protein bio-signature to predict cystic fibrosis pulmonary exacerbations (04/2015-03/2017)
  • Boehringer-Ingelheim – A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with “Systemic Sclerosis associated Interstitial Lung Disease” (01/2016-2018)
  • Boehringer-Ingelheim – A twelve week, open-label, randomized, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) (12/2015-2018)
  • ProMetic – A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients with Idiopathic Pulmonary Fibrosis (IPF) (09/2015-2017)
  • BC Lung Association – Researching Frailty, Sarcopenia, and Healthcare costs in Fibrotic ILD Study: The REFReSH – ILD Study (10/2015-09/2017)
  • Boehringer-Ingelheim – High Oxygen deliver to Preserve Exercise capacity in IPF patients treated with nintedanib: The HOPE-IPF Study (12/2015-12/2018)
  • Gilead – Exploring the mechanisms of inhaled aztreonam lysine clinical efficacy in individuals with cystic fibrosis and chronic Pseudomonas aeruginosa infection (2015-2017)
  • Vertex Pharmaceuticals – A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (661-106) (2015-2018)
  • Vertex – A Phase 3, Randomized Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function (661-108) (2015-2018)
  • Pharmaxis – Long Term Administration of Inhaled Manmitol in Cystic Fibrosis – A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects (2015-2017)
  • CIHR – The Scleroderma Patient – Centered Intervention Network (SPIN) COHORT (2014-2017)
  • Vertex Pharmaceuticals Inc. – A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (809-105) (2014-2015)
  • Vertex Pharmaceuticals Inc. – Clinical and Economic Burden of Illness Study of Cystic Fibrosis Patients Homozygous for F508del Mutation – Retrospective Chart Review Study (2014-2016)
  • InterMune – Inspiration-Plus: A Phase IV study evaluating the use of pirfenidone in idiopathic pulmonary fibrosis (09/2014-2017)
  • Boehringer-Ingelheim – Impact of nintedanib on high-resolution computed tomography fibrosis score in idiopathic pulmonary fibrosis (04/2014-2016)
  • InterMune – UBC Interstitial lung disease summer studentship (05/2014-09/2016)
  • Boehringer-Ingelheim – Interstitial lung disease research training program (07/2014-06/2016)
  • Intermune – Frailty in fibrotic interstitial lung disease (10/2014-09/2017)
  • Gilead – A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) (06/2013-2016)